Sucampo Pharmaceuticals, Inc. (SCMP) Given Consensus Rating of “Buy” by Brokerages
Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) has been given a consensus rating of “Buy” by the eleven brokerages that are covering the firm, MarketBeat reports. Four equities research analysts have rated the stock with a hold rating and six have given a buy rating to the company. The average 12 month price objective among analysts that have issued a report on the stock in the last year is $17.86.
Several equities research analysts have recently weighed in on SCMP shares. Zacks Investment Research raised Sucampo Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research report on Tuesday, July 4th. ValuEngine upgraded Sucampo Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Friday, June 23rd. Mizuho lowered Sucampo Pharmaceuticals from a “buy” rating to a “neutral” rating and cut their target price for the company from $14.00 to $12.00 in a research note on Tuesday, October 3rd. TheStreet lowered Sucampo Pharmaceuticals from a “c+” rating to a “d” rating in a research note on Wednesday, August 2nd. Finally, Maxim Group set a $23.00 target price on Sucampo Pharmaceuticals and gave the company a “buy” rating in a research note on Wednesday, August 2nd.
WARNING: This report was first posted by American Banking News and is owned by of American Banking News. If you are reading this report on another website, it was copied illegally and reposted in violation of US & international copyright and trademark law. The original version of this report can be accessed at https://www.americanbankingnews.com/2017/10/12/sucampo-pharmaceuticals-inc-scmp-given-consensus-rating-of-buy-by-brokerages.html.
Sucampo Pharmaceuticals (NASDAQ:SCMP) last posted its quarterly earnings data on Wednesday, August 2nd. The biopharmaceutical company reported $0.28 earnings per share for the quarter, beating the consensus estimate of $0.22 by $0.06. Sucampo Pharmaceuticals had a positive return on equity of 56.58% and a negative net margin of 61.99%. The company had revenue of $59.90 million during the quarter, compared to analysts’ expectations of $56.44 million. During the same period in the prior year, the business earned $0.24 earnings per share. Sucampo Pharmaceuticals’s revenue for the quarter was up 15.3% compared to the same quarter last year. On average, equities research analysts expect that Sucampo Pharmaceuticals will post $1.01 earnings per share for the current fiscal year.
In related news, major shareholder Sachiko Kuno sold 1,000,000 shares of the firm’s stock in a transaction dated Monday, September 11th. The stock was sold at an average price of $12.00, for a total value of $12,000,000.00. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Jones W. Bryan purchased 4,700 shares of the firm’s stock in a transaction that occurred on Friday, August 4th. The stock was purchased at an average price of $10.60 per share, for a total transaction of $49,820.00. Following the acquisition, the insider now owns 4,700 shares of the company’s stock, valued at $49,820. The disclosure for this purchase can be found here. Company insiders own 4.13% of the company’s stock.
A number of institutional investors have recently bought and sold shares of SCMP. Louisiana State Employees Retirement System boosted its holdings in Sucampo Pharmaceuticals by 1.0% in the second quarter. Louisiana State Employees Retirement System now owns 10,200 shares of the biopharmaceutical company’s stock valued at $107,000 after acquiring an additional 100 shares during the last quarter. First Citizens Bank & Trust Co. bought a new position in Sucampo Pharmaceuticals in the second quarter valued at about $116,000. JPMorgan Chase & Co. bought a new position in Sucampo Pharmaceuticals in the second quarter valued at about $117,000. Karp Capital Management Corp bought a new position in Sucampo Pharmaceuticals in the first quarter valued at about $119,000. Finally, Pinnacle Associates Ltd. bought a new position in Sucampo Pharmaceuticals in the second quarter valued at about $122,000. Institutional investors and hedge funds own 55.46% of the company’s stock.
Sucampo Pharmaceuticals Company Profile
Sucampo Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of pharmaceutical products. Its primary focus areas are gastroenterology, ophthalmology and oncology-related disorders. Its product candidates include VTS-270, Lubiprostone (AMITIZA), Unoprostone is opropyl (RESCULA) and CPP-1X/sulindac combination product.
Receive News & Ratings for Sucampo Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sucampo Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.